NASDAQ NMS - GLOBAL MARKET · ALEC
-1.54% · -$0.0300 · Vol Not reported
Pre-market · updated 06:16:27 ET
Alector Inc

Alector Inc

Biotechnology
$1.89
Card
Relationship Map

Follow $ALEC

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ALEC by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
ALEC
Alector Inc
Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

80/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALEC moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALEC catalysts
About Alector Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2019
Employees
103
Country
US

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.92
Last session
Day high
$1.92
Last session
Day low
$1.92
Last session
Previous close
$1.92
52W high
$3.31
-42.89% from high
52W low
$1.14
35% of range
Market cap
$214.4M
EPS
$-1.0919
Beta
1.12
Shares out
111.7M
Avg volume
4.6M
VWAP
$1.92
Last session
Price history computed in-house
1W
+1.63%
1M
-23.47%
3M
+17.42%
1Y
-38.62%
YTD
+21.18%
SMA 50 $2.04 · below
SMA 200 $2.00 · below
52W position 35%

ALEC overview

Veridion Score
80
Registered · 2026-10-07
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALEC.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALEC Form 4 filings
Public disclosures

Congress activity in ALEC

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

ALEC contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALEC in this window.
Lobbying spend

ALEC lobbying filings, year to date.

Registered lobbying filings matched to Alector Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALEC in this window.
Loading news for ALEC
Analyst ratings
Sovereign unlock shows live analyst consensus for ALEC.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.